EA201992703A1 - Композиции для лечения фиброза - Google Patents

Композиции для лечения фиброза

Info

Publication number
EA201992703A1
EA201992703A1 EA201992703A EA201992703A EA201992703A1 EA 201992703 A1 EA201992703 A1 EA 201992703A1 EA 201992703 A EA201992703 A EA 201992703A EA 201992703 A EA201992703 A EA 201992703A EA 201992703 A1 EA201992703 A1 EA 201992703A1
Authority
EA
Eurasian Patent Office
Prior art keywords
agonists
present
compositions
treating fibrosis
methods
Prior art date
Application number
EA201992703A
Other languages
English (en)
Inventor
Брайан Лиан
Хироко Масамуне
Джеффри И. Баркер
Original Assignee
Вайкинг Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вайкинг Терапьютикс, Инк. filed Critical Вайкинг Терапьютикс, Инк.
Publication of EA201992703A1 publication Critical patent/EA201992703A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Настоящее изобретение относится к способам лечения фиброзных состояний путем введения агонистов рецептора тиреоидных гормонов (TR). В настоящем изобретении предложены способы, в которых снижается аномальное отложение компонентов внеклеточного матрикса, таких как коллаген, кератин или эластин, либо посредством взаимодействия агонистов TR с зависимыми от трансформирующего фактора роста бета (TGF-) воспалительными путями, либо с помощью других механизмов, в результате чего улучшается течение фиброзных симптомов.
EA201992703A 2017-06-05 2018-06-04 Композиции для лечения фиброза EA201992703A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762515421P 2017-06-05 2017-06-05
PCT/US2018/035909 WO2018226604A1 (en) 2017-06-05 2018-06-04 Compositions for the treatment of fibrosis

Publications (1)

Publication Number Publication Date
EA201992703A1 true EA201992703A1 (ru) 2020-04-15

Family

ID=64566664

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992703A EA201992703A1 (ru) 2017-06-05 2018-06-04 Композиции для лечения фиброза

Country Status (11)

Country Link
US (1) US11707472B2 (ru)
EP (1) EP3634426A4 (ru)
JP (1) JP7168660B2 (ru)
KR (1) KR102600115B1 (ru)
CN (1) CN110996966A (ru)
AU (2) AU2018280118B2 (ru)
BR (1) BR112019025659A2 (ru)
CA (1) CA3064940A1 (ru)
EA (1) EA201992703A1 (ru)
MX (1) MX2022008451A (ru)
WO (1) WO2018226604A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
CN110198719A (zh) 2016-11-21 2019-09-03 维京治疗公司 治疗糖原贮积病的方法
CA3064940A1 (en) 2017-06-05 2018-12-13 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
WO2019005816A1 (en) 2017-06-29 2019-01-03 Yale University COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING FIBROUS PULMONARY DISEASES
US11787828B2 (en) 2018-03-22 2023-10-17 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
US20220016137A1 (en) * 2018-12-05 2022-01-20 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
US11752161B2 (en) * 2020-03-27 2023-09-12 Gannex Pharma Co., Ltd. Pharmaceutical compositions, method of making and method of using thereof
EP4125822A1 (en) * 2020-03-27 2023-02-08 Gannex Pharma Co., Ltd. Pharmaceutical compositions, method of making and method of using thereof

Family Cites Families (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3120551A (en) 1961-03-20 1964-02-04 Warner Lambert Pharmaceutical 5-(4-biphenylyl)-3-methylvaleric acid and functional derivatives thereof
US3357887A (en) 1962-12-03 1967-12-12 Upjohn Co 4-phenoxy-3, 5-dihalophenylalkanols and hypocholesteremic compositions containing the same
US4069343A (en) 1973-03-23 1978-01-17 American Home Products Corporation Oxamic acid derivatives for the prevention of immediate type hypersensitivity reactions
US4069347A (en) 1976-08-02 1978-01-17 Emery Industries, Inc. Compositions of quaternary ammonium derivatives of lanolin acids
US4426453A (en) 1980-09-18 1984-01-17 Amersham International Limited Derivatives of iodothyronine compounds and their use in an assay for the free iodothyronine compounds
DE3037858A1 (de) 1980-10-07 1982-05-19 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von reaktiven, kupplungsfaehigen derivaten der schilddruesenhormone t (pfeil abwaerts)3(pfeil abwaerts) und t (pfeil abwaerts)4(pfeil abwaerts) und deren verwendung
US4554290A (en) 1983-06-17 1985-11-19 Ciba-Geigy Corporation Oxamic acid derivatives
US4673691A (en) 1984-11-05 1987-06-16 Nicholas Bachynsky Human weight loss inducing method
GB8501372D0 (en) 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
US5061798A (en) 1985-01-18 1991-10-29 Smith Kline & French Laboratories, Ltd. Benzyl pyridyl and pyridazinyl compounds
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
US5091552A (en) 1986-06-30 1992-02-25 Board Of Regents, The University Of Texas System Novel antitumor aldophosphamide analogs
DE3718638A1 (de) 1987-06-04 1988-12-22 Thomae Gmbh Dr K Neue phenylethanolamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US4929600A (en) 1988-03-18 1990-05-29 University Of Deleware Endocrine manipulation to improve body composition of poultry
US5116828A (en) 1989-10-26 1992-05-26 Nippon Zoki Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of osteoporosis
IE903851A1 (en) 1989-11-03 1991-05-08 Boots Pharma Inc Iodothyronine polymers
JP3084059B2 (ja) 1990-02-05 2000-09-04 ビーティージー・インターナショナル・インコーポレーテッド 甲状腺ホルモン心臓治療
US5158978A (en) 1990-02-05 1992-10-27 British Technology Group (U.S.A.) Thyroid hormone treatment of acute cardiovascular compromise
ATE167679T1 (de) 1990-09-14 1998-07-15 Acad Of Science Czech Republic Wirkstoffvorläufer von phosphonaten
NO924985L (no) 1991-12-30 1993-07-01 Akzo Nv Thyroaktiv blanding med vedvarende frigjoering
US5284971A (en) 1992-07-16 1994-02-08 Syntex (U.S.A.) Inc. 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents
ES2108855T3 (es) 1992-07-21 1998-01-01 Ciba Geigy Ag Derivados de acido oxamico como agentes hipocolesteremicos.
US5741803A (en) 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
US5571840A (en) 1993-06-22 1996-11-05 The Regents Of The University Of Michigan Method for treating central nervous system ischemia
US5519163A (en) 1993-10-15 1996-05-21 Merck & Co., Inc. Inhibitors of phosphoinositide-specific phospholipase C
GB9401892D0 (en) 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
AU1942995A (en) 1994-03-15 1995-10-03 K.U. Leuven Research & Development New use of growth hormone
GB9416219D0 (en) 1994-08-11 1994-10-05 Karobio Ab Receptor ligands
DE19502209A1 (de) 1995-01-25 1996-08-01 Hoechst Ag Phosphonoessigsäure-Derivate und deren Verwendung zur Behandlung von degenerativen Gelenkserkrankungen
AU6476996A (en) 1995-06-07 1996-12-30 Karo Bio Ab Novel uses for thyroid hormones or thyroid hormone-like comp ounds
US6221911B1 (en) 1995-06-07 2001-04-24 Karo Bio Ab Uses for thyroid hormone compounds or thyroid hormone-like compounds
US6380255B1 (en) 1995-06-07 2002-04-30 Karo Bio Ab Treatment for dermal skin atrophy using thyroid hormone compounds or thyroid hormone-like compounds
EP0873361B1 (en) 1995-12-13 2006-11-02 The Regents Of The University Of California Crystals of the ligand-binding domain of the thyroid hormone receptor complexed to a ligand
US6266622B1 (en) 1995-12-13 2001-07-24 Regents Of The University Of California Nuclear receptor ligands and ligand binding domains
US6361992B1 (en) 1996-05-08 2002-03-26 The United States Of America As Represented By The Department Of Health And Human Services Thyroid stimulating hormone superagonists
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
TR199900066T2 (xx) 1996-07-18 1999-04-21 Pfizer Inc. Matriks metalloproteazlar�n fosfinat bazl� inhibit�rleri
JP3345428B2 (ja) 1996-08-20 2002-11-18 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 合成甲状腺ホルマン組成物を使用した眼の処置
SK282548B6 (sk) 1996-10-24 2002-10-08 Novartis Ag Substituované aminoalkánfosfónové kyseliny, spôsob ich prípravy, farmaceutické prostriedky, ktoré ich obsahujú, a ich použitie
AU2089297A (en) 1997-03-17 1998-10-12 Yun K. Tam Composition for prevention of hepatic steatosis
US5951989A (en) 1997-04-07 1999-09-14 Heymann; Warren R. Method for the treatment of dry skin
US5883294A (en) 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs
GB9713739D0 (en) 1997-06-27 1997-09-03 Karobio Ab Thyroid receptor ligands
US5922775A (en) 1997-10-23 1999-07-13 Octamer, Inc. Method of treating malignant tumors with ketone thyroxine analogues having no significant hormonal activity
EP1037636A4 (en) 1997-12-11 2004-08-18 Univ Oxford INHIBITATION OF MEMBRANE-TIED VIRAL REPLICATION
AU2586999A (en) 1998-02-03 1999-08-16 University Of Arkansas, The Method for the stimulation of sperm production and gonadal development in animals
WO1999045016A2 (en) 1998-03-06 1999-09-10 Metabasis Therapeutics, Inc. Novel prodrugs for phosphorus-containing compounds
DE69905877T2 (de) 1998-06-02 2003-11-20 Arthromics Plc Wilmslow Substanzen, die mit dem thyroid-hormonrezeptor interagieren, zur behandlung fibrotischer erkrankungen
ATE293595T1 (de) 1998-06-30 2005-05-15 Univ California Thyroidhormon-analoga und verfahren zu ihrer herstellung
GB9816935D0 (en) 1998-08-05 1998-09-30 Karobio Ab Novel glucocortoid and thyroid receptor ligands for the treatment of metabolic disorders
EP0994570A1 (en) 1998-10-12 2000-04-19 Sony International (Europe) GmbH Spread spectrum channel estimator with inter-path interference cancellation
GB9828442D0 (en) 1998-12-24 1999-02-17 Karobio Ab Novel thyroid receptor ligands and method II
ATE264333T1 (de) 1999-02-23 2004-04-15 Ono Pharmaceutical Co Medikamente, die derivate der phosphorigensäure als aktiven inhaltsstoff enthalten
US6344481B1 (en) 1999-03-01 2002-02-05 Pfizer Inc. Thyromimetic antiobesity agents
ID29889A (id) 1999-03-01 2001-10-18 Pfizer Prod Inc Asam-asam oksamat dan turunan-turunannya sebagai ligan-ligan reseptor tiroid
PT1033364E (pt) 1999-03-01 2005-07-29 Pfizer Prod Inc Ciano com acidos oxamicos e derivados como ligandos de receptores de tiroide
EP1165570B9 (en) 1999-03-05 2007-02-21 Metabasis Therapeutics, Inc. Novel phosphorus-containing prodrugs
CO5160290A1 (es) 1999-03-29 2002-05-30 Novartis Ag Derivados de acido fenoxifeniloxamico sustituido .
US6790978B2 (en) 1999-03-29 2004-09-14 Novartis Ag Thyromimetic organic compounds
US6599942B1 (en) 1999-03-29 2003-07-29 Novartis Ag Thyromimetic organic compounds
US6776984B1 (en) 1999-08-20 2004-08-17 George R. Schwartz Induced regeneration and repair of damaged neurons and nerve axon myelin
DE60012502T2 (de) 1999-05-05 2005-07-28 Merck & Co., Inc. Neue cathechole als antimikrobielle mittel
US6468755B1 (en) 1999-08-10 2002-10-22 Joslin Diabetes Center, Inc. Method for identifying compounds for treatment of insulin resistance
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
EP1210354A1 (en) 1999-09-08 2002-06-05 Metabasis Therapeutics, Inc. Prodrugs for liver specific drug delivery
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US6787652B1 (en) 1999-09-30 2004-09-07 Pfizer, Inc. 6-Azauracil derivatives as thyroid receptor ligands
US6627660B1 (en) 1999-11-16 2003-09-30 New River Pharmaceuticals Inc. Stabilized thyroxine compounds
GB9927056D0 (en) 1999-11-17 2000-01-12 Karobio Ab Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
EP1127882A1 (en) 2000-01-25 2001-08-29 Pfizer Products Inc. Tetrazole compounds as thyroid receptor ligands
AU3092901A (en) 2000-02-17 2001-08-27 Bristol Myers Squibb Co Aniline-derived ligands for the thyroid receptor
US6852706B1 (en) 2000-03-22 2005-02-08 The Wistar Institute Methods and compositions for healing heart wounds
US6664291B2 (en) 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
IL151376A0 (en) 2000-03-31 2003-04-10 Pfizer Prod Inc Malonamic acids and derivatives thereof as thyroid receptor ligands
WO2001079287A2 (en) 2000-04-17 2001-10-25 Sa Majesté La Reine Du Chef Du Canada - Agriculture Et Agroalimentaire Canada Steatosis-modulating factors and uses thereof
US6620830B2 (en) 2000-04-21 2003-09-16 Pfizer, Inc. Thyroid receptor ligands
US6395784B1 (en) 2000-06-07 2002-05-28 Bristol-Myers Squibb Company Benzamide ligands for the thyroid receptor
GB0015205D0 (en) 2000-06-21 2000-08-09 Karobio Ab Bioisosteric thyroid receptor ligands and method
AU2001271875A1 (en) 2000-07-06 2002-01-21 Delsys Pharmaceutical Corporation Improved thyroid hormone formulations
US20030186847A1 (en) 2000-07-10 2003-10-02 Jones Richard Henry Insulin derivatives and synthesis thereof
AU2002224596A1 (en) 2000-08-01 2002-02-13 Shionogi And Co., Ltd. Preventives or remedies for obesity or fatty liver
IL137672A0 (en) 2000-08-03 2001-10-31 Dpharm Ltd Derivatives of branched-chain lipophilic molecules and uses thereof
DE10038007A1 (de) 2000-08-04 2002-02-14 Bayer Ag Neue Amino-und Amido-Diphenylether für Arzneimittel
WO2002015845A2 (en) 2000-08-21 2002-02-28 Merck & Co., Inc. Anti-hypercholesterolemic drug combination
DE10046029A1 (de) 2000-09-18 2002-03-28 Bayer Ag Indazole
WO2002026752A1 (en) 2000-09-27 2002-04-04 Ilex Oncology Research S.A. α-SUBSTITUTED β-AMINOETHYL PHOSPHONATES
WO2002032408A2 (en) 2000-10-20 2002-04-25 Novartis Ag Combinations of a thyromimetic compound and a statin
JP2004517851A (ja) 2000-12-27 2004-06-17 バイエル アクチェンゲゼルシャフト 甲状腺受容体のリガンドとしてのインドール誘導体
US6982348B2 (en) 2001-01-26 2006-01-03 Takeda Pharmaceutical Company Limited Aminoethanol derivatives
AU2002228317A1 (en) 2001-01-29 2002-08-12 Insight Strategy And Marketing Ltd Benz-1,3-azole derivatives and their uses as heparanase inhibitors
US6716877B2 (en) 2001-01-31 2004-04-06 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method to treat chronic heart failure and/or elevated cholesterol levels
US6534676B2 (en) 2001-01-31 2003-03-18 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same
AU2002237298B2 (en) 2001-02-08 2006-08-03 Karo Bio Ab Phenoxy substituted benzocondensed heteroaryl derivatives as thyroid receptor ligands
WO2002066017A1 (en) 2001-02-20 2002-08-29 Abbott Laboratories Liothyronine sodium and levothyroxine sodium combination
WO2002072528A1 (en) 2001-03-14 2002-09-19 Eli Lilly And Company Fluorinated trienes and their use as rxr modulators
DE10115408A1 (de) 2001-03-29 2002-10-02 Bayer Ag Benzofuran-Derivate
US6825201B2 (en) 2001-04-25 2004-11-30 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic amidopiperazine derivatives
GB0111861D0 (en) 2001-05-15 2001-07-04 Karobio Ab Novel compounds
FR2825926A1 (fr) 2001-06-14 2002-12-20 Sod Conseils Rech Applic Derives d'imidazoles modulant les canaux sodiques
WO2003003013A1 (en) 2001-06-29 2003-01-09 University Of Massachusetts Non-nuclear effects of thyroid hormone
ATE381542T1 (de) 2001-08-13 2008-01-15 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
AU2002341555A1 (en) 2001-08-14 2003-09-02 King Pharmaceuticals, Inc. Levothyroxine pharmaceutical compositions, methods of making and methods of administration
JP2005507381A (ja) 2001-08-24 2005-03-17 カロ バイオ アクチェブラーグ 心臓障害および代謝障害の治療のための主要環置換甲状腺受容体アンタゴニスト
ATE313325T1 (de) 2001-09-26 2006-01-15 Pfizer Prod Inc Indolcaroboxylsäure als thyroidrezeptor-liganden
US6806381B2 (en) 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
EP1442028A4 (en) 2001-11-06 2009-11-04 Bristol Myers Squibb Co SUBSTITUTED ACID DERIVATIVES, WHICH APPRECIATE AS ANTIDIBILICS AND AGENTS AGAINST OBESITAS, AND METHODS
US6831102B2 (en) 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
WO2003061567A2 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
EP1471049A4 (en) 2002-01-30 2006-08-16 Kissei Pharmaceutical NEW THYROIDIAN HORMONE RECEPTOR LIGAND, MEDICINAL PREPARATIONS CONTAINING THE SAME AND USE THEREOF
AU2003211022A1 (en) 2002-02-19 2003-09-09 Ilex Products, Inc. Aminodiphosphonate apolipoprotein e modulators
WO2003075835A2 (en) 2002-03-04 2003-09-18 Smithkline Beecham Corporation Compositions and methods for regulating thyroid hormone metabolism and cholesterol and lipid metabolism via the nuclear receptor car
JP2005521430A (ja) 2002-03-25 2005-07-21 アプレーラ コーポレイション レポーター酵素変異体相補体を用いた核レセプター機能の検出のためのシステムおよび方法
GB0208384D0 (en) 2002-04-11 2002-05-22 Karobio Ab Novel compounds
WO2003094845A2 (en) 2002-05-08 2003-11-20 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
EP1364962A1 (en) 2002-05-24 2003-11-26 Stichting tot bevordering van de wetenschap der Endocrinologie Use of monocarboxylate transporter proteins for thyroid hormone transport
AU2003248676A1 (en) 2002-06-15 2003-12-31 Enteromed, Inc. Treatment of non-alcoholic fatty liver disease
US20040137441A1 (en) 2003-01-15 2004-07-15 Isis Pharmaceuticals Inc. Modulation of thyroid hormone receptor interactor 3 expression
JP5685355B2 (ja) 2002-07-04 2015-03-18 ジーランド ファーマ アクティーゼルスカブ Ｇｌｐ−１および糖尿病の処置方法
GEP20084475B (en) 2002-07-09 2008-09-10 Bristol Myers Squibb Co Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method for their production
GB0215978D0 (en) 2002-07-10 2002-08-21 Karobio Ab Novel compounds
AU2003268078A1 (en) 2002-08-10 2004-02-25 King Pharmaceuticals, Inc. Levothyroxine compositions and methods
GB0219022D0 (en) 2002-08-15 2002-09-25 Karobio Ab Novel thyromimetic compounds
WO2004026097A2 (en) 2002-09-19 2004-04-01 First Circle Medical, Inc. Treatment of steatosis using hyperthermia
AU2003290613A1 (en) 2002-11-05 2004-06-07 New River Pharmaceuticals Inc. Controlled absorption of mixed thyroyd hormone formulations
ITMI20022777A1 (it) 2002-12-27 2004-06-28 Altergon Sa Formulazioni farmaceutiche per ormoni tiroidei e procedimenti per il loro ottenimento.
US20040142868A1 (en) 2003-01-21 2004-07-22 Sleeman Mark W. Method of treating liver steatosis in a mammal
EP1587783A4 (en) 2003-01-24 2006-11-08 Bristol Myers Squibb Co CYCLOALKYL-CONTAINING ANILID LIGANDS FOR THE THYROID RECEPTOR
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
EP1606018A2 (en) 2003-03-05 2005-12-21 ZymoGenetics, Inc. Use of thyroid-stimulating hormone to induce lipolysis
AU2003901813A0 (en) 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Pharmaceutical derivatives
US7557143B2 (en) 2003-04-18 2009-07-07 Bristol-Myers Squibb Company Thyroid receptor ligands
WO2004103289A2 (en) 2003-05-14 2004-12-02 New York University Driverse thyroid hormone receptor antagonists and uses thereof
ITRM20030363A1 (it) 2003-07-24 2005-01-25 Fernando Goglia Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
KR20060079190A (ko) 2003-08-14 2006-07-05 아사히 가세이 파마 가부시키가이샤 치환 아릴알칸산 유도체 및 그의 용도
US6952844B2 (en) 2003-08-27 2005-10-11 Danaher Thomas C Bed-tent
WO2005028488A1 (en) 2003-09-12 2005-03-31 Quatrx Pharmaceuticals Co. Heteroaryl phosphinyl and thiophosphinyl compounds for regulation of glucose, triglycerides, and ldl/hdl levels
US20070066681A1 (en) 2003-09-26 2007-03-22 Chugai Seiyaku Kaushiki Kaisha Pharmaceutical composition for treating fatty liver or hepatic disease
KR20060096487A (ko) 2003-10-27 2006-09-11 진랩스 테크놀러지스, 인크. 바이러스 감염증들을 치료하기 위한 뉴클레오시드 화합물
EP1689383B1 (en) 2003-11-19 2012-10-31 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
CN103374041B (zh) 2004-06-08 2017-05-10 症变治疗公司 路易斯酸介导的环状酯的合成
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
CA2606497A1 (en) 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
RU2007148927A (ru) * 2005-05-26 2009-07-10 Метабэйзис Терапьютикс, Инк. (Us) Новые тиреомиметики, содержащие фосфиновую кислоту
DK1919878T3 (da) 2005-07-21 2010-10-25 Hoffmann La Roche Pyridazinonderivater som thyroidhormonreceptoragonister
US20080261913A1 (en) * 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
WO2009089093A1 (en) 2008-01-04 2009-07-16 Quatrx Pharmaceuticals Company Thyroid hormone receptor agonists
CA2732686C (en) 2008-12-22 2017-10-03 Otonomy, Inc. Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
WO2011038207A1 (en) * 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
US20150045389A1 (en) 2012-04-10 2015-02-12 Trustees Of Dartmouth College Compounds and methods for inhibiting cif virulence factor
US9587403B2 (en) 2014-04-29 2017-03-07 Platinum Roofing, Inc. Fixture support for membrane roof
US9913819B2 (en) * 2014-06-12 2018-03-13 Yale University Methods of treating or preventing fibrotic lung diseases
RU2018113437A (ru) 2015-09-16 2019-10-17 Тобира Терапьютикс, Инк. Комбинированная терапия с использованием ценикривирока для лечения фиброза
CN109071577A (zh) 2016-04-22 2018-12-21 症变治疗公司 甲状腺激素受体激动剂及其用途
MX2018014743A (es) 2016-06-03 2019-04-11 Chemocentryx Inc Metodo para tratar fibrosis hepatica.
US20190255080A1 (en) 2016-09-16 2019-08-22 Viking Therapeutics, Inc. Method of reducing thyroid-associated side effects
CN110198719A (zh) * 2016-11-21 2019-09-03 维京治疗公司 治疗糖原贮积病的方法
WO2018104916A1 (en) 2016-12-09 2018-06-14 Cadila Healthcare Limited Treatment for primary biliary cholangitis
WO2018193007A1 (en) 2017-04-18 2018-10-25 Genfit Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor
CA3064940A1 (en) 2017-06-05 2018-12-13 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
WO2019005816A1 (en) 2017-06-29 2019-01-03 Yale University COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING FIBROUS PULMONARY DISEASES
CN107469086A (zh) 2017-07-31 2017-12-15 深圳市润佳通科技有限公司 甲状腺素受体类似物及其盐或前药在制备治疗和/或预防肺部疾病的药物中的应用
US20220016137A1 (en) 2018-12-05 2022-01-20 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
KR20210099612A (ko) 2018-12-05 2021-08-12 바이킹 테라퓨틱스 인코포레이티드 간 장애의 치료를 위한 조성물 및 방법

Also Published As

Publication number Publication date
AU2018280118B2 (en) 2021-07-15
AU2018280118A1 (en) 2019-12-19
US11707472B2 (en) 2023-07-25
US20200179412A1 (en) 2020-06-11
AU2021245185A1 (en) 2021-11-04
EP3634426A4 (en) 2021-04-07
JP7168660B2 (ja) 2022-11-09
JP2020522569A (ja) 2020-07-30
KR102600115B1 (ko) 2023-11-09
CN110996966A (zh) 2020-04-10
EP3634426A1 (en) 2020-04-15
KR20200011485A (ko) 2020-02-03
CA3064940A1 (en) 2018-12-13
MX2022008451A (es) 2022-08-11
WO2018226604A1 (en) 2018-12-13
BR112019025659A2 (pt) 2020-08-25

Similar Documents

Publication Publication Date Title
EA201992703A1 (ru) Композиции для лечения фиброза
MD3806955T2 (ro) Agoniști ai receptorului GLP-1 și utilizările acestora
CL2017002526A1 (es) Uso de agonistas de receptor de péptido formilo 2 para tratar enfermedades inflamatorias oculares (divisional de solicitud n°2485-2015)
EA202190485A1 (ru) Соединения, модулирующие fxr (nr1h4)
ECSP14003642A (es) 4-fenil-piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1
CR20150493A (es) Composiciones de amri contra el componente c5 del complemento y métodos para su uso
BRPI1010587A2 (pt) métodos para aumentar adipócitos termogênicos
MX357761B (es) Métodos para tratar la enfermedad de alzheimer, enfermedad de huntington, autismo u otros trastornos.
PH12014502141A1 (en) New indanyloxydihydrobenzofuranylacetic acid derivatives and their use as gpr40 receptor agonists
EA201501122A8 (ru) Новые агонисты соматостатиновых рецепторов подтипа 4 (sstr4)
CO6290770A2 (es) Nuevos derivados de insulina con perfil tiempo/accion extremadamente retardado
EA202191566A1 (ru) Соединения, модулирующие fxr (nr1h4)
BR112014016461A2 (pt) método para a estabilização de fibra de lignina para a posterior conversão em fibra de carbono
MX2019015350A (es) Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de la fibrosis.
BR112014011641A2 (pt) composto; composição; uso de um composto; método para tratar pelo menos uma doença, distúrbio ou condição selecionada de obesidade, sobrepeso ou distribuição de gordura anormal e condições ou doenças associadas com os mesmos em um sujeito em necessidade do mesmo; método para remodelar tecido adiposo branco para tecido adiposo tipo marrom em um sujeito; método para tratar uma doença, distúrbio ou condição associada com ou se beneficiando da remodelação de tecido adiposo branco para tecido adiposo tipo marrom em um sujeito; e método para reduzir o tecido adiposo branco (wat) em um sujeito em necessidade do mesmo
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
WO2020081410A3 (en) Radioligands for imaging the lpa1 receptor
MX2021001272A (es) Composiciones de bismuto-tiol y metodos de uso.
EA201501123A8 (ru) Новые (циано-диметил-метил)-изоксазолы и -[1,3,4]тиадиазолы
MX2022000945A (es) Composicion para incrementar la expresion de pgc-1alfa.
EA202092695A1 (ru) Композиции, содержащие глюкозу и гемицеллюлозу, и их применение
BR112016021000A2 (pt) Composições e métodos para prevenir ou tratar dis-função crônica do aloenxerto de pulmão (clad) e fi-brose pulmonar idiopática (ipf)
MX2022007670A (es) Compuestos antihelminticos que comprenden una estructura de quinolina.
MX2022007671A (es) Compuestos antihelminticos que comprenden una estructura de azaindoles.
ZA202107825B (en) Pharmaceutical parenteral composition of dual glp1/2 agonist